Luisa Fernanda Riaño-Sánchez

Dr. Luisa Fernanda Riaño-Sánchez

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
LRLuisa Fernanda Riaño-Sánchez
Luisa Fernanda Riaño-Sánchez
CACarlos Alvarez-Moreno
Carlos Alvarez-Moreno
MGMarcela Godoy-Corredor
Marcela Godoy-Corredor
CSClaudia Rocío Sierra
Claudia Rocío Sierra
MCMargarita Inés Castañeda
Margarita Inés Castañeda
JCJorge Alberto Cortes
Jorge Alberto Cortes
In critically ill patients, identification of the pathogen may allow for the timely adjustment of antibiotics and improved outcomes. Background/Objectives: The aim of the study was to assess whether performing a multiplex PCR pneumonia panel (PN-panel) in patients with pneumonia in the intensive care unit (ICU) had any effect on mortality or other important clinical outcomes. Methods: A retrospective cohort study was conducted on adult patients with pneumonia who required ICU admission in four institutions in Bogotá between November 2019 and June 2023. Mortality at 30 days, the length of the hospital and ICU stay, the duration of antibiotics, and their association with the PN-panel performance were evaluated using an inverse probability of the treatment weighting to adjust for covariates and potential confounders. Results: A total of 304 patients were included, including 150 with PN-panel, with a mean age of 65.0 years (SD 14.6). SARS-CoV-2 was the primary etiologic agent in 186 (61.2%) patients, and 256 (84.2%) patients had community-acquired pneumonia. No association was found between 30-day mortality and the PN-panel, with a HR of 1.14 (CI 95% 0.76–1.70), although the assessment by an infectious disease specialist was associated with a lower mortality HR of 0.29 (CI 95% 0.19–0.45). There was no association between the PN-panel and antimicrobial therapy duration or other clinical outcomes. Conclusions: The use of the PN-panel was not associated with changes in mortality, the duration of antibiotics, or hospital and ICU stays. To acquire greater rational decision-making, microbiological data produced by this test should be interpreted with aid of an antimicrobial stewardship program oriented by an infectious disease team that could take the clinical data and integrate the information provided.

13 September 2026 in Infectio
Verified
Journal Article
Open access
PDF file
CSCarlos Saavedra
Carlos Saavedra
ACAlejandra Contreras-Torres
Alejandra Contreras-Torres
DCDiego Cruz-Acevedo
Diego Cruz-Acevedo
DRDiego Rodriguez-Lugo
Diego Rodriguez-Lugo
EPEduardo José Polanía-Guzmán
Eduardo José Polanía-Guzmán
JCJose Leonardo Cely-Andrade
Jose Leonardo Cely-Andrade
Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud. Cuarta Edición. Recomendaciones basadas en consenso de expertos e informadas en la evidencia